NTRP Neurotrope Inc.

1.18
0  0%
Previous Close 1.18
Open 1.18
Price To Book 0.81
Market Cap 15,420,267
Shares 13,068,023
Volume 1,100,411
Short Ratio
Av. Daily Volume 469,763
Stock charts supplied by TradingView

NewsSee all news

  1. Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value

    NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its plans to explore strategic

  2. Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease

    NEW YORK, Sept. 9, 2019 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released May 1, 2017 - primary endpoint not met.
Bryostatin
Alzheimer's disease
Phase 2 trial did not meet primary endpoint - September 9, 2019.
Bryostatin
Alzheimer's disease

Latest News

  1. Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value

    NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its plans to explore strategic

  2. Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease

    NEW YORK, Sept. 9, 2019 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today